<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>At warp speed:</title>
    <meta charset="utf-8" />
    <meta name="author" content="David Benkeser, PhD MPH   Emory University  Department of Biostatistics and Bioinformatics" />
    <link href="index_files/font-awesome-5.3.1/css/fontawesome-all.min.css" rel="stylesheet" />
    <link rel="stylesheet" href="xaringan-themer.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: center, middle, inverse, title-slide

# At warp speed:
## Statistics and COVID-19 vaccine development
### David Benkeser, PhD MPH<br> <span style="font-size: 75%;"> Emory University<br> Department of Biostatistics and Bioinformatics </span>
### <i class="fab  fa-twitter "></i> <a href = 'https://twitter.com/biosbenk' style = 'color: white;'><span class="citation">@biosbenk</span></a> <br> <i class="fab  fa-github "></i> <a href = 'https://bit.ly/warpspeedstats' style = 'color: white;'>bit.ly/warpspeedstats</a> <br>

---




&lt;style type="text/css"&gt;
.remark-slide-content {
    font-size: 22px
}
&lt;/style&gt;

## SARS-CoV-2 Infection

&lt;img src="img/sarscov2infection.png" height="450px" style="display: block; margin: auto;" /&gt;

.small[from [Washington Post](https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update-coronavirus/)]

---

## Nucleic acid vaccines

&lt;img src="img/nucleicacidvax.png" height="300px" style="display: block; margin: auto;" /&gt;
.pull-left[.center[
__Examples__: 

Moderna (mRNA)

Pfizer (mRNA)
]]

.pull-right[.center[
.blue2[+] Quick manufacturing

.red[-] Potentially challenging cold chain

.red[-] Never been approved before
]]

???

Figures again borrowed from WaPo. See also the [Nature news article](https://www.nature.com/articles/d41586-020-01221-y) about COVID vaccines. 

---

## Viral-vectored vaccines

&lt;img src="img/viralvectorvax.png" height="300px" style="display: block; margin: auto;" /&gt;
.pull-left[.center[
__Examples__: 

AstraZeneca (chimp adeno)

Janssen (human adeno)
]]

.pull-right[.center[
.blue2[+] Quick manufacturing

.red[-] Immunity against vector 

.red[-] Unintentional effects on &lt;a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32156-5/fulltext"&gt; HIV risk&lt;/a&gt;?
]]

---

## Subunit vaccines

&lt;img src="img/subunitvax.png" height="300px" style="display: block; margin: auto;" /&gt;
.pull-left[.center[
__Examples__: 

NovaVax

Sanofi Pasteur/GSK 
]]

.pull-right[.center[
.blue2[+] Construct of several effective vaccines (hep B, HPV, ...)

.red[-] Slower manufacturing

.red[-] Often require an adjuvant
]]

---

## Weakened/inactivated vaccines

&lt;img src="img/inactivevax.png" height="300px" style="display: block; margin: auto;" /&gt;
.pull-left[.center[
__Examples__: 

Sinopharm

Sinovac
]]

.pull-right[.center[
.blue2[+] Construct of several effective vaccines (MMR, polio, flu)

.red[-] Slower manufacturing

.red[-] Often require an adjuvant
]]

---

&lt;img src="img/owsprocess.jpeg" height="575px" style="display: block; margin: auto;" /&gt;

.small[from [DoD](https://www.defense.gov/Explore/Spotlight/Coronavirus/Operation-Warp-Speed/)]

???

Two main ways companies can interface with OWS: 
* purchasing/manufacturing funding
* OWS-run trials (agreements through BARDA @ NIH)

---

## COVID-19 Prevention Network

[CoVPN](https://www.coronaviruspreventionnetwork.org/) was [formed by NIAID](https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trials-network-test-covid-19-vaccines-other-prevention-tools) to establish a unified clinical trial network for evaluating vaccines and monoclonal antibodies.

* pooling of resources across __four existing trials networks__
* clinical sites, laboratories, recruitment specialists, statisticians, ...

.pull-left[

&lt;img src="img/covpn.png" height="250px" style="display: block; margin: auto;" /&gt;

]

.pull-right[__Statisticians__ advise on: 

* primary trial __design and analysis__
* sequential __efficacy monitoring__
* __safety__ monitoring
* DSMB/FDA comments
* __immune correlates__

]

---
class: inverse, center, middle

.huge[Design and analysis]

---

## AstraZeneca design

Trial protocols have (unusually) been made publicly available.

* [Moderna](https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf), [Pfizer](https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf), [AZ](https://s3.amazonaws.com/ctr-med-7111/D8110C00001/52bec400-80f6-4c1b-8791-0483923d0867/c8070a4e-6a9d-46f9-8c32-cece903592b9/D8110C00001_CSP-v2.pdf), [Janssen](https://www.jnj.com/coronavirus/covid-19-phase-3-study-clinical-protocol)

All Phase III trials are largely similar to this: 

&lt;img src="img/azdesign.png" height="275px" style="display: block; margin: auto;" /&gt;

* .small[.red[vaccine], .blue2[immune response], .gray[phone call], clinic visit]

---

## What is primary hypothesis test?

Vaccine efficacy, `\(\text{VE}\)`, is the __percent reduction in relative risk__ comparing vaccine to placebo. 

$$
\text{VE} = 1 - \frac{\text{‚Äúrisk‚Äù in vaccine}}{\text{‚Äúrisk‚Äù in placebo}}
$$

* `\(\text{‚Äúrisk‚Äù}\)` of what? See next slides.
* `\(\text{‚Äúrisk‚Äù}\)` quantified by hazard, cumulative incidence, incidence rate, ...
  * in rare event setting, all similar

[FDA guidance](https://www.fda.gov/media/139638/download) (pg. 14) stipulates: 
* a point estimate of `\(\text{VE}\)` for the primary endpoint of at
least 50% __and__ 
* lower bound of an appropriately adjusted confidence interval &gt;30%.
* overall type I error control for one-sided test at 2.5%. 

---

## How is `\(\text{VE}\)` estimated/tested?

|__Company__ | __Estimation approach__                     |
|:-----------|:--------------------------------------------|
|Pfizer      |Bayesian beta-binomial                       |
|Moderna     |Cox model                                    |
|AZ          |Poisson regression model                     |
|Janssen     |Binomial + sequential probability ratio test |

&lt;br&gt; 

Simulation studies showed __little difference in power__ across approaches. 

---

## What is the most relevant endpoint?

&lt;img src="img/endpt.png" height="400px" style="display: block; margin: auto;" /&gt;

&lt;br&gt;

.small[from Mehrotra et al doi: [10.7326/M20-6169](https://www.doi.org/10.7326/M20-6169)]

---

## What is the most relevant endpoint?

__SARS-CoV-2 infection__
* .blue2[+] relevant to stemming spread, many infections will be observed
* .red[-] clinically relevant? measured coarsely in time; many false positives

__COVID__
* .blue2[+] more clinically relevant, reasonable number of cases expected
* .red[-] clinically relevant if symptoms are mild?

__Severe COVID__
* .blue2[+] most clinically relevant, a-priori highest expected efficacy
* .red[-] very few cases expected to be observed, longer evaluation needed

---

## What is the most relevant endpoint?

__Burden of disease (BOD)__
* .blue2[+] more clinically relevant than COVID
* .blue2[+] lower power for .red[vaccines of questionable benefit]
* .blue2[+] power at least as high as COVID for .blue1[likely vaccine profiles]
* .red[-] best way to assign burden score? treating ordinal as continuous ü§∑‚Äç‚ôÇÔ∏è

&lt;img src="img/bodpower.png" height="250px" style="display: block; margin: auto;" /&gt;

---

## What is the most relevant endpoint?

[FDA guidance](https://www.fda.gov/media/139638/download) (pg. 13) states __either COVID or SARS-CoV-2 infection__ is an acceptable primary endpoint.
  *  OWS guidance to companies has been that __infection alone__ is __not acceptable__ as primary endpoint. 

&lt;br&gt; 

FDA guidance states companies, "should consider __powering efficacy trials__ for formal hypothesis testing on a __severe COVID endpoint__ [or] evaluate as a __secondary endpoint__."
  * Only Janssen so far is powering for severe COVID as primary.


---
class: inverse, center, middle

.huge[Results (so far)]

---

## Placeholder

A table summarizing Phase III trial results so far (Pfizer, Moderna, AZ)

---

class: inverse, center, middle

.huge[Vaccine correlates]

---

## Correlates of protection

&lt;img src="img/correlates.png" height="400px" style="display: block; margin: auto;" /&gt;

.small[From Plotkin and Gilbert, doi: [10.1093/cid/cis238](https://doi.org/10.1093/cid/cis238)]

---

## Correlates of protection

If an CoP is established to __reliably predict vaccine efficacy__, then subsequent efficacy trials may use the CoP as the __primary endpoint__. 

Accelerates approval for: 

* different populations (e.g., children, pregnant women);
* new vaccines in the same class in same/different populations.

&lt;br&gt; 

In effect: 

.center[.large[__A CoP is a candidate surrogate endpoint.__]]

---

## Measuring correlates

Running assays on &gt;30k samples is .red[expensive] and __statistically unnecessary__.

Instead we __measure immune responses__ in:

* a stratified random subcohort (\~1600 individuals)
* all SARS-CoV-2 and COVID endpoints

This is a __case-cohort design__ ([Prentice, 1986](https://www.jstor.org/stable/2336266?seq=1)), a special case of a __two-phase sampling design__ ([Breslow, 2009](https://academic.oup.com/aje/article/169/11/1398/159218)).

* Phase 1: measure baseline variables, vaccine, endpoint __on everyone__
* Phase 2: given baseline, vaccine, endpoint, select members of __immune response subcohort__ with some (known) probability

---

## Placeholder

A slide with high-level heuristics about correlates: 
* causal sufficiency, causal mediation

---

## Estimation in two-phase designs

.pull-left[
* `\(W\)` = baseline covariates
* `\(A\)` = vaccine assignment
* `\(Y\)` = COVID endpoint
]

.pull-right[
* `\(\Delta\)` = indicator of being in immune response subcohort
* `\(\Delta S\)` = measure of immune responses `\(S\)`
]

Suppose we are interested in `\(E(S)\)`. Use __Horvitz-Thompson/IPTW estimator__: $$
\hat{\mu} = \frac{1}{n}\sum_{i=1}^n \frac{\Delta_i}{P(\Delta = 1 \mid W_i, A_i, Y_i)} S_i \ . 
$$

More efficient to use __augmented estimator__: 
$$
\hat{\mu} + \frac{1}{n}\sum_{i=1}^n \left(1 - \frac{\Delta_i}{P(\Delta = 1 \mid W_i, A_i, Y_i)} \right) \hat{E}(S \mid \Delta = 1, A_i, W_i, Y_i) \ . 
$$

???

Intuition: if `\(Y\)` or `\(W\)` is perfectly predictive of `\(S\)`, then `\(\hat{E}(S \mid \Delta = 1, A_i, W_i, Y_i)\)` is like imputing the true value. So it's like we measured `\(S\)` on more people!

It turns out that consistency of `\(\hat{\mu}\)` is not impacted by model for `\(S\)` -- double robustness.

---

## Estimation in two-phase designs

This augmented approach [generalizes](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083136/). In [Hejazi et al, 2020](https://onlinelibrary.wiley.com/doi/abs/10.1111/biom.13375?af=R) we study $$
\psi_{\delta} = E[P(Y = 1 \mid A = 1, W, S = S + \delta)] \ .
$$

With assumptions, `\(\psi_{\delta}\)` = __counterfactual risk__ with vaccine AND `\(\delta\)` change in `\(S\)`. 

.pull-left[

&lt;img src="img/shiftparm.png" height="250px" style="display: block; margin: auto;" /&gt;

]

.pull-right[

* examine over a range of `\(\delta\)` and summarize by projecting onto working model

* compare to risk in placebo for controlled effects-type parameter

]

---

## Placeholder

Challenges for correlates in face of highly effective vaccines
* low case numbers, stability of estimators?

Establishment of correlate will have to draw from NHP studies, natural infection data, other sources.

---

## Placeholder

Topics for discussion/open questions:
* Durability -- will we be able to continue blinded, placebo-controlled follow-up
  * I'm basically hearing the answer is "No!"
* Long term safety -- people still seem skeptical of mRNA vaccines wrt long term outcomes
* Bridging to children
* Importance of VE against infection
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script>var slideshow = remark.create({
"highlightStyle": "tomorrow-night-blue",
"highlightLanguage": "rmarkdown",
"highlightLines": false
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  // Replace <script> tags in slides area to make them executable
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    var scriptAttrs = scripts[i].attributes;
    for (var j = 0; j < scriptAttrs.length; j++) {
      s.setAttribute(scriptAttrs[j].name, scriptAttrs[j].value);
    }
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
